Blueprint Medicines: Q4 Earnings Snapshot

CAMBRIDGE, Mass. (AP) — CAMBRIDGE, Mass. (AP) — Blueprint Medicines Corp. (BPMC) on Thursday reported a loss of $110.9 million in its fourth quarter.

The Cambridge, Massachusetts-based company said it had a loss of $1.82 per share.

The results topped Wall Street expectations. The average estimate of 11 analysts surveyed by Zacks Investment Research was for a loss of $2.04 per share.

The cancer drug developer posted revenue of $72 million in the period, also beating Street forecasts. Ten analysts surveyed by Zacks expected $67.3 million.

For the year, the company reported that its loss narrowed to $507 million, or $8.37 per share. Revenue was reported as $249.4 million.

Blueprint Medicines shares have fallen 17% since the beginning of the year. The stock has climbed 73% in the last 12 months.

_____

This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on BPMC at https://www.zacks.com/ap/BPMC